PRPO – Precipio Inc

PRPO — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

0.38

Margin Of Safety %

-23

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

25.86

Target Price

Analyst Recom

Performance Q

7.85

Upside

-115.1%

Beta

1.18

Ticker: PRPO

16 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-03	PRPO	25.16	N/A	N/A	0
2026-03-04	PRPO	26.98	N/A	N/A	0
2026-03-06	PRPO	26.63	N/A	N/A	0
2026-03-09	PRPO	25.66	N/A	N/A	0
2026-03-10	PRPO	26.9	N/A	N/A	0
2026-03-11	PRPO	27.93	N/A	N/A	0
2026-03-12	PRPO	28.77	N/A	N/A	0
2026-03-13	PRPO	28.77	N/A	N/A	0
2026-03-17	PRPO	29.35	N/A	N/A	0
2026-03-18	PRPO	28.19	N/A	N/A	0
2026-03-20	PRPO	27.16	N/A	N/A	0
2026-03-25	PRPO	27.33	N/A	N/A	0
2026-03-26	PRPO	26.5	N/A	N/A	0
2026-03-27	PRPO	25.42	N/A	N/A	0
2026-03-30	PRPO	24.25	N/A	N/A	0
2026-03-31	PRPO	25	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

16 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	PRPO	24.83	-	-	-
2026-03-03	PRPO	24.84	-	-	-
2026-03-04	PRPO	26.93	-	-	-
2026-03-05	PRPO	26.10	-	-	-
2026-03-06	PRPO	26.35	-	-	-
2026-03-09	PRPO	26.02	-	-	-
2026-03-10	PRPO	26.90	-	-	-
2026-03-11	PRPO	27.50	-	-	-
2026-03-12	PRPO	28.77	-	-	-
2026-03-13	PRPO	27.40	-	-	-
2026-03-17	PRPO	29.40	-	-	-
2026-03-18	PRPO	29.15	-	-	-
2026-03-19	PRPO	27.49	-	-	-
2026-03-20	PRPO	27.50	-	-	-
2026-03-23	PRPO	26.94	-	-	-
2026-03-24	PRPO	26.86	-	-	-
2026-03-25	PRPO	27.23	-	-	-
2026-03-26	PRPO	27.18	-	-	-
2026-03-27	PRPO	25.19	-	-	-
2026-03-30	PRPO	24.25	-	-	-
2026-03-31	PRPO	25.86	-	-	-
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	PRPO	-4.04	-4.84	0.24
2026-03-03	PRPO	-4.04	-4.84	0.24
2026-03-04	PRPO	-4.04	-4.84	0.24
2026-03-05	PRPO	-4.01	-4.84	0.24
2026-03-06	PRPO	-4.04	-4.84	0.24
2026-03-09	PRPO	-4.02	-4.87	0.24
2026-03-10	PRPO	-4.02	-4.87	0.24
2026-03-11	PRPO	0.05	-4.87	0.22
2026-03-12	PRPO	0.05	-4.87	0.22
2026-03-13	PRPO	0.05	-4.87	0.22
2026-03-18	PRPO	0.05	-4.86	0.22
2026-03-19	PRPO	0.05	-4.86	0.22
2026-03-20	PRPO	0.05	-4.86	0.22
2026-03-23	PRPO	0.05	-4.84	0.22
2026-03-24	PRPO	0.05	-4.84	0.22
2026-03-25	PRPO	0.05	-4.84	0.38
2026-03-26	PRPO	0.05	-4.84	0.38
2026-03-27	PRPO	0.05	-4.84	0.38
2026-03-30	PRPO	0.05	-4.84	0.38
2026-03-31	PRPO	0.05	-4.84	0.38
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

0.05

Institutional Transactions

-4.84

Beta

1.18

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

20.01

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

85.9

Max Drawdown 5-Year %

-95.8

Target Price

P/E

Forward P/E

PEG

P/S

1.82

P/B

3.06

P/Free Cash Flow

121.65

EPS

-0.29

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1.51

Relative Volume

0.68

Return on Equity vs Sector %

-36.6

Return on Equity vs Industry %

-20.2

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

◆ PRPO Healthcare

$25.00

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

2/20

Pullback

15/25

Volume

9/15

Valuation

5/20

TP/AR

2/10

Options

0/10

RSI

Range 1M

29.4%

Sup Dist

6.9%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

4/25

Growth

11/30

Estimates

2/20

Inst/Vol

2/15

Options

0/10

EPS Yr

EPS NY

52W%

82.3%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🔴 SELL -21.6% upside

Quality

4/30

Valuation

4/30

Growth

5/25

Stability

4/10

LT Trend

0/5

Upside

-21.6%

Quality

MoS

-23%

Precipio, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 54

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.

PRPO

Latest News

—

Caricamento notizie per PRPO…

stock quote shares PRPO – Precipio Inc Stock Price stock today

news today PRPO – Precipio Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch PRPO – Precipio Inc yahoo finance google finance

stock history PRPO – Precipio Inc invest stock market

stock prices PRPO premarket after hours

ticker PRPO fair value insiders trading

PRPH – ProPhase Labs Inc

PRPH — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

0.54

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

0.08

Target Price

160

Analyst Recom

Performance Q

-93.37

Upside

N/A

Beta

-0.54

Ticker: PRPH

16 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-03	PRPH	0.135	N/A	N/A	0
2026-03-04	PRPH	0.15	N/A	N/A	0
2026-03-06	PRPH	0.1301	N/A	N/A	0
2026-03-09	PRPH	0.1364	N/A	N/A	0
2026-03-10	PRPH	0.1411	N/A	N/A	0
2026-03-11	PRPH	0.1494	N/A	N/A	0
2026-03-12	PRPH	0.14	N/A	N/A	0
2026-03-13	PRPH	0.1489	N/A	N/A	0
2026-03-17	PRPH	0.1	N/A	N/A	0
2026-03-18	PRPH	0.09	N/A	N/A	0
2026-03-20	PRPH	0.0872	N/A	N/A	0
2026-03-25	PRPH	0.0839	N/A	N/A	0
2026-03-26	PRPH	0.072	N/A	N/A	0
2026-03-27	PRPH	0.0775	N/A	N/A	0
2026-03-30	PRPH	0.0811	N/A	N/A	0
2026-03-31	PRPH	0.1099	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

16 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	PRPH	0.15	-	-	-
2026-03-03	PRPH	0.15	-	-	-
2026-03-04	PRPH	0.15	-	-	-
2026-03-05	PRPH	0.15	-	-	-
2026-03-06	PRPH	0.15	-	-	-
2026-03-09	PRPH	0.14	-	-	-
2026-03-10	PRPH	0.14	-	-	-
2026-03-11	PRPH	0.14	-	-	-
2026-03-12	PRPH	0.15	-	-	-
2026-03-13	PRPH	0.15	-	-	-1.55
2026-03-17	PRPH	0.12	-	-	-1.55
2026-03-18	PRPH	0.09	-	-	-1.55
2026-03-19	PRPH	0.09	-	-	-1.55
2026-03-20	PRPH	0.08	-	-	-1.55
2026-03-23	PRPH	0.09	-	-	-1.55
2026-03-24	PRPH	0.09	-	-	-1.55
2026-03-25	PRPH	0.10	-	-	-1.55
2026-03-26	PRPH	0.08	-	-	-1.55
2026-03-27	PRPH	0.07	-	-	-1.55
2026-03-30	PRPH	0.07	-	-	-1.55
2026-03-31	PRPH	0.08	-	-	-1.55
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

Last Quarter Act. EPS

-0.16

Avg. EPS Est. Current Quarter

-0.41

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

-0.54

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

100

Max Drawdown 5-Year %

-100

Target Price

160

P/E

Forward P/E

PEG

P/S

P/B

0.22

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y

-1.55

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

-635.3

Return on Equity vs Industry %

-618.9

EPS 1 7Days Diff

EPS 1 30Days Diff

-1.18

EBIT Estimation

No data found for PRPH

ProPhase Labs, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 96

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

PRPH

Latest News

—

Caricamento notizie per PRPH…

stock quote shares PRPH – ProPhase Labs Inc Stock Price stock today

news today PRPH – ProPhase Labs Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch PRPH – ProPhase Labs Inc yahoo finance google finance

stock history PRPH – ProPhase Labs Inc invest stock market

stock prices PRPH premarket after hours

ticker PRPH fair value insiders trading

NEO – Neogenomics Inc.

NEO — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

6.54

Margin Of Safety %

Put/Call OI Ratio

0.11

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

0.16

Price

7.43

Target Price

13.94

Analyst Recom

2.29

Performance Q

-39.67

Upside

-496.2%

Beta

1.73

Ticker: NEO

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-02	NEO	9.46	0.13	1.60	9497
2026-03-03	NEO	9.53	0.13	0.04	9505
2026-03-04	NEO	9.1	0.13	0.50	9515
2026-03-05	NEO	9.14	0.13	0.00	9520
2026-03-06	NEO	8.96	0.13	999.99	9520
2026-03-09	NEO	8.93	0.13	0.00	9521
2026-03-10	NEO	8.52	0.13	0.00	9521
2026-03-11	NEO	8.56	0.12	0.63	9487
2026-03-12	NEO	7.99	0.12	1.30	9485
2026-03-13	NEO	7.98	0.12	1.30	9485
2026-03-17	NEO	8.27	0.12	999.99	9526
2026-03-18	NEO	8.01	0.12	999.99	9526
2026-03-19	NEO	8.19	0.12	0.02	9513
2026-03-20	NEO	7.94	0.12	0.38	9456
2026-03-23	NEO	8.11	0.12	0.00	9391
2026-03-24	NEO	7.87	0.12	0.80	9652
2026-03-25	NEO	7.78	0.12	0.00	9673
2026-03-26	NEO	7.75	0.12	0.00	9563
2026-03-27	NEO	7.18	0.12	0.03	9558
2026-03-30	NEO	7.2	0.11	999.99	10689
2026-03-31	NEO	7.43	0.11	1.00	10689
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	NEO	9.49	0.0	-	0.16
2026-03-03	NEO	9.55	0.0	-	0.16
2026-03-04	NEO	9.09	0.0	-	0.16
2026-03-05	NEO	9.14	0.0	-	0.16
2026-03-06	NEO	8.96	0.0	-	0.16
2026-03-09	NEO	8.92	0.0	-	0.16
2026-03-10	NEO	8.56	0.0	-	0.16
2026-03-11	NEO	8.55	0.0	-	0.16
2026-03-12	NEO	7.99	0.0	-	0.16
2026-03-13	NEO	7.88	0.0	-	0.16
2026-03-17	NEO	8.27	0.0	-	0.16
2026-03-18	NEO	8.00	0.0	-	0.16
2026-03-19	NEO	8.19	0.0	-	0.16
2026-03-20	NEO	7.95	0.0	-	0.16
2026-03-23	NEO	8.09	0.0	-	0.16
2026-03-24	NEO	7.86	0.0	-	0.16
2026-03-25	NEO	7.77	0.0	-	0.16
2026-03-26	NEO	7.75	0.0	-	0.16
2026-03-27	NEO	7.19	0.0	-	0.16
2026-03-30	NEO	7.20	0.0	-	0.16
2026-03-31	NEO	7.43	0.0	-	0.16
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	NEO	-2.22	6.69	6.95
2026-03-03	NEO	-2.22	6.69	6.95
2026-03-04	NEO	-2.22	6.69	6.95
2026-03-05	NEO	-2.22	6.69	6.95
2026-03-06	NEO	-2.22	6.69	6.95
2026-03-09	NEO	-2.22	6.75	6.95
2026-03-10	NEO	-2.22	6.75	6.95
2026-03-11	NEO	-2.22	6.75	6.61
2026-03-12	NEO	-2.22	6.75	6.61
2026-03-13	NEO	-2.22	6.75	6.61
2026-03-17	NEO	-2.22	6.71	6.61
2026-03-18	NEO	-2.22	6.71	6.61
2026-03-19	NEO	-2.22	6.71	6.61
2026-03-20	NEO	-2.22	6.71	6.61
2026-03-23	NEO	-2.22	6.71	6.61
2026-03-24	NEO	-2.22	6.71	6.61
2026-03-25	NEO	-2.22	6.71	6.54
2026-03-26	NEO	-2.22	6.71	6.54
2026-03-27	NEO	-2.22	6.71	6.54
2026-03-30	NEO	-2.22	6.71	6.54
2026-03-31	NEO	-2.22	6.71	6.54
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

0.04

Insider Transactions

-2.22

Institutional Transactions

6.71

Beta

1.73

Average Sales Estimate Current Quarter

184

Average Sales Estimate Next Quarter

196

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

86.4

Max Drawdown 5-Year %

-90.8

Target Price

13.94

P/E

Forward P/E

23.64

PEG

0.43

P/S

1.32

P/B

1.14

P/Free Cash Flow

EPS

-0.84

Average EPS Est. Cur. Y

0.16

EPS Next Y. (Est.)

0.32

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-14.85

Relative Volume

0.67

Return on Equity vs Sector %

-40.3

Return on Equity vs Industry %

-24

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.02

EBIT Estimation

◆ NEO Healthcare

$7.42

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

0/20

Pullback

11/25

Volume

9/15

Valuation

15/20

TP/AR

3/10

Options

7/10

RSI

28.6

Range 1M

13.4%

Sup Dist

4.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

0/25

Growth

21/30

Estimates

4/20

Inst/Vol

5/15

Options

5/10

EPS Yr

43.4%

EPS NY

82.5%

52W%

30.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +61.5% upside

Quality

5/30

Valuation

19/30

Growth

18/25

Stability

8/10

LT Trend

0/5

Upside

+61.5%

Quality

NeoGenomics, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 2500

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

NEO

Latest News

—

Caricamento notizie per NEO…

stock quote shares NEO – Neogenomics Inc. Stock Price stock today

news today NEO – Neogenomics Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch NEO – Neogenomics Inc. yahoo finance google finance

stock history NEO – Neogenomics Inc. invest stock market

stock prices NEO premarket after hours

ticker NEO fair value insiders trading

MYGN – Myriad Genetics, Inc.

MYGN — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

13.15

Margin Of Safety %

Put/Call OI Ratio

0.27

EPS Next Q Diff

EPS Last/This Y

4.01

EPS This/Next Y

0.11

Price

4.5

Target Price

7.39

Analyst Recom

Performance Q

-28.68

Upside

-3,172.2%

Beta

1.83

Ticker: MYGN

16 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-03	MYGN	5.28	0.09	2.74	1708
2026-03-04	MYGN	5.29	0.13	0.24	1775
2026-03-06	MYGN	5.16	0.14	0.00	1785
2026-03-09	MYGN	4.8	0.14	0.00	1791
2026-03-10	MYGN	5.11	0.14	0.05	1765
2026-03-11	MYGN	5.07	0.13	0.58	1817
2026-03-12	MYGN	4.86	0.14	132.00	1835
2026-03-13	MYGN	4.85	0.14	132.00	1835
2026-03-17	MYGN	4.79	0.14	11.00	1858
2026-03-18	MYGN	4.63	0.17	0.00	1892
2026-03-20	MYGN	4.59	0.17	1.00	1986
2026-03-25	MYGN	4.67	0.21	0.00	974
2026-03-26	MYGN	4.62	0.21	0.00	974
2026-03-27	MYGN	4.28	0.22	0.50	1093
2026-03-30	MYGN	4.37	0.22	1.23	1102
2026-03-31	MYGN	4.5	0.27	0.00	1184
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

16 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	MYGN	5.01	-108.6	426.0	0.06
2026-03-03	MYGN	5.28	-108.6	425.8	0.06
2026-03-04	MYGN	5.28	-108.6	391.6	0.06
2026-03-05	MYGN	5.14	-108.6	391.4	0.06
2026-03-06	MYGN	5.16	-108.6	391.6	0.06
2026-03-09	MYGN	4.79	-123.7	391.2	0.06
2026-03-10	MYGN	5.11	-123.7	392.0	0.06
2026-03-11	MYGN	5.07	-123.7	391.5	0.06
2026-03-12	MYGN	4.86	-123.7	391.4	0.06
2026-03-13	MYGN	4.67	-123.7	391.4	0.06
2026-03-17	MYGN	4.78	-123.7	391.9	0.06
2026-03-18	MYGN	4.63	-123.7	391.4	0.06
2026-03-19	MYGN	4.76	-123.7	390.1	0.06
2026-03-20	MYGN	4.58	-123.7	389.9	0.06
2026-03-23	MYGN	4.64	-123.7	390.0	0.06
2026-03-24	MYGN	4.60	-123.7	390.0	0.06
2026-03-25	MYGN	4.68	-123.7	390.1	0.06
2026-03-26	MYGN	4.62	-123.7	390.0	0.06
2026-03-27	MYGN	4.29	-123.7	389.7	0.06
2026-03-30	MYGN	4.36	-123.7	389.7	0.06
2026-03-31	MYGN	4.50	-123.7	389.9	0.06
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	MYGN	2.35	2.45	12.11
2026-03-03	MYGN	2.35	2.45	12.11
2026-03-04	MYGN	2.35	2.45	12.11
2026-03-05	MYGN	2.35	2.45	12.11
2026-03-06	MYGN	2.35	2.45	12.11
2026-03-09	MYGN	2.35	2.44	12.11
2026-03-10	MYGN	3.28	2.44	12.11
2026-03-11	MYGN	3.28	2.44	13.07
2026-03-12	MYGN	3.28	2.44	13.07
2026-03-13	MYGN	3.28	2.44	13.07
2026-03-18	MYGN	3.28	2.60	13.07
2026-03-19	MYGN	3.28	2.60	13.07
2026-03-20	MYGN	3.28	2.60	13.07
2026-03-23	MYGN	3.28	2.58	13.07
2026-03-24	MYGN	3.28	2.58	13.07
2026-03-25	MYGN	3.28	2.58	13.15
2026-03-26	MYGN	3.28	2.58	13.15
2026-03-27	MYGN	3.28	2.58	13.15
2026-03-30	MYGN	3.28	2.60	13.15
2026-03-31	MYGN	3.28	2.60	13.15
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.02

Avg. EPS Est. Current Quarter

-0.07

Avg. EPS Est. Next Quarter

0.02

Insider Transactions

3.28

Institutional Transactions

2.6

Beta

1.83

Average Sales Estimate Current Quarter

202

Average Sales Estimate Next Quarter

215

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

87.8

Max Drawdown 5-Year %

-89.5

Target Price

7.39

P/E

Forward P/E

31.37

PEG

0.53

P/S

0.51

P/B

1.14

P/Free Cash Flow

EPS

-3.95

Average EPS Est. Cur. Y

0.06

EPS Next Y. (Est.)

0.17

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-44.38

Relative Volume

0.73

Return on Equity vs Sector %

-126.9

Return on Equity vs Industry %

-110.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

389.9

◆ MYGN Healthcare

$4.50

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

0/20

Pullback

16/25

Volume

9/15

Valuation

15/20

TP/AR

0/10

Options

8/10

RSI

43.1

Range 1M

19.5%

Sup Dist

5.6%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

0/25

Growth

13/30

Estimates

0/20

Inst/Vol

4/15

Options

6/10

EPS Yr

-24.6%

EPS NY

217.2%

52W%

13.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +41.3% upside

Quality

6/30

Valuation

14/30

Growth

12/25

Stability

7/10

LT Trend

1/5

Upside

+41.3%

Quality

Myriad Genetics, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 2700

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

MYGN

Latest News

—

Caricamento notizie per MYGN…

stock quote shares MYGN – Myriad Genetics, Inc. Stock Price stock today

news today MYGN – Myriad Genetics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch MYGN – Myriad Genetics, Inc. yahoo finance google finance

stock history MYGN – Myriad Genetics, Inc. invest stock market

stock prices MYGN premarket after hours

ticker MYGN fair value insiders trading

MTD – Mettler-Toledo International, Inc.

[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol= #%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]

stock_superchart: please set a ticker attribute.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

ticker required

Beta

[iframe https://widget.finnhub.io/widgets/historical-eps?symbol= 589 360 ]

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

[iframe https://widget.finnhub.io/widgets/recommendation?symbol= 589 450 ]

[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol= 589 450 ]

Sector:

Industry:

Employees:

[News_ _Stock]

stock quote shares MTD – Mettler-Toledo International, Inc. Stock Price stock today

news today MTD – Mettler-Toledo International, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch MTD – Mettler-Toledo International, Inc. yahoo finance google finance

stock history MTD – Mettler-Toledo International, Inc. invest stock market

stock prices premarket after hours

ticker fair value insiders trading

GENE – Genetic Technologies Ltd. ADR

[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=GENE #%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]

GENE — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

0.76

Target Price

6.87

Analyst Recom

Performance Q

-14.99

Upside

N/A

Beta

1.11

Ticker: GENE

16 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-03	GENE	0.765	N/A	N/A	0
2026-03-04	GENE	0.765	N/A	N/A	0
2026-03-06	GENE	0.765	N/A	N/A	0
2026-03-09	GENE	0.765	N/A	N/A	0
2026-03-10	GENE	0.765	N/A	N/A	0
2026-03-11	GENE	0.765	N/A	N/A	0
2026-03-12	GENE	0.765	N/A	N/A	0
2026-03-13	GENE	0.765	N/A	N/A	0
2026-03-17	GENE	0.765	N/A	N/A	0
2026-03-18	GENE	0.765	N/A	N/A	0
2026-03-20	GENE	0.765	N/A	N/A	0
2026-03-25	GENE	0.765	N/A	N/A	0
2026-03-26	GENE	0.765	N/A	N/A	0
2026-03-27	GENE	0.765	N/A	N/A	0
2026-03-30	GENE	0.765	N/A	N/A	0
2026-03-31	GENE	0.765	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

16 items 1 of 1

[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=GENE 589 360 ]

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

1.11

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

98.5

Max Drawdown 5-Year %

-97.7

Target Price

6.87

P/E

Forward P/E

PEG

P/S

1.24

P/B

2.89

P/Free Cash Flow

EPS

-1.83

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-156.76

Relative Volume

Return on Equity vs Sector %

-680.2

Return on Equity vs Industry %

-667.2

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

[iframe https://widget.finnhub.io/widgets/recommendation?symbol=GENE 589 450 ]

[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=GENE 589 450 ]

No data found for GENE

[News_GENE _Stock]

stock quote shares GENE – Genetic Technologies Ltd. ADR Stock Price stock today

news today GENE – Genetic Technologies Ltd. ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch GENE – Genetic Technologies Ltd. ADR yahoo finance google finance

stock history GENE – Genetic Technologies Ltd. ADR invest stock market

stock prices GENE premarket after hours

ticker GENE fair value insiders trading

PRPO – Precipio Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: PRPO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

PRPH – ProPhase Labs Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: PRPH

No data found

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y